Research Analysts’ Recent Ratings Changes for West Pharmaceutical Services (WST)

A number of firms have modified their ratings and price targets on shares of West Pharmaceutical Services (NYSE: WST) recently:

• 6/9/2026 – West Pharmaceutical Services was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $400.00 price target on the stock, up from $310.00.
• 6/2/2026 – West Pharmaceutical Services had its “overweight” rating reaffirmed by Stephens. They now have a $360.00 price target on the stock.
• 6/1/2026 – West Pharmaceutical Services is now covered by Wolfe Research. They set an “outperform” rating and a $375.00 price target on the stock.
• 6/1/2026 – West Pharmaceutical Services was upgraded by Wolfe Research to “outperform”. They now have a $375.00 price target on the stock.
• 5/29/2026 – West Pharmaceutical Services had its price target raised by Morgan Stanley from $315.00 to $325.00. They now have an “equal weight” rating on the stock.
• 5/13/2026 – West Pharmaceutical Services was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/27/2026 – West Pharmaceutical Services was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 4/27/2026 – West Pharmaceutical Services was given a new $315.00 price target by Morgan Stanley.
• 4/27/2026 – West Pharmaceutical Services had its price target raised by Barclays PLC from $275.00 to $310.00. They now have an “equal weight” rating on the stock.
• 4/24/2026 – West Pharmaceutical Services had its “buy” rating reaffirmed by Citigroup Inc..
• 4/24/2026 – West Pharmaceutical Services had its “outperform” rating reaffirmed by Evercore Inc.
• 4/14/2026 – West Pharmaceutical Services was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/14/2026 – West Pharmaceutical Services had its price target raised by Barclays PLC from $265.00 to $275.00. They now have an “equal weight” rating on the stock.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, CAO Chad Winters sold 896 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the transaction, the chief accounting officer directly owned 1,523 shares in the company, valued at approximately $457,920.41. This represents a 37.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. The trade was a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.60% of the company’s stock.

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.